Thoracoscopic Thymectomy for Juvenile Myasthenia Gravis

Juvenile Myasthenia Gravis (JMG) is an organ-specific autoimmune disorder of neuromuscular transmission. The primary pathophysiology involves abnormal thymic lymphoid hyperplasia and loss of central self-tolerance within the thymic microenvironment. In this setting, autoreactive T-lymphocytes stimulate B-cells to synthesize pathogenic autoantibodies directed against the nicotinic acetylcholine receptors (anti-AChR) or muscle-specific kinase (anti-MuSK) at the motor endplate. These autoantibodies block receptor binding sites, accelerate receptor endocytosis, and trigger complement-mediated destruction of the post-synaptic junctional folds, resulting in failure of neuromuscular transmission and fatigable muscle weakness. This autoimmune breakdown is an intrinsic biological process. It is entirely unrelated to visual screen exposure, academic or emotional stress, sleep hygiene, or dietary habits. Because the hyperplastic thymus acts as both the primary source of antigen sensitization and the reservoir of antibody-producing plasma cells, radical thymectomy eliminates the driving immunological nidus, providing up to a 70% probability of complete, sustained medication-free remission.